Here’s what you should know:
1. Exact Sciences increased sales 148 percent year-over-year for the fourth quarter and 168 percent year-over-year for fiscal year 2017.
2. Exact Sciences completed 176,000 Cologuard tests during the fourth quarter of 2017, an increase of 115 percent, year-over-year.
3. For the year, Exact Sciences completed a total of 571,000 Cologuard tests, a 134 percent increase over 2016.
4. Exact Sciences CEO Kevin Conroy said in a release, “An increasing number of people are being screened for colon cancer with our accurate, non-invasive test. As demand for Cologuard strengthens, we will continue to invest in our team, facilities and infrastructure to support the company’s long-term growth.”
5. Exact Sciences will report its 2017 financial results in February.
More articles on gastroenterology:
GI leader to know: Dr. Alexandra Read of Puget Sound Gastroenterology
OrphoMed taps GI expert Dr. Mark Sostek for CMO position — 3 insights
Takeda to acquire TiGenix for $628M — 4 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
